<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564174</url>
  </required_header>
  <id_info>
    <org_study_id>33762</org_study_id>
    <secondary_id>CIHR 37749</secondary_id>
    <nct_id>NCT00564174</nct_id>
  </id_info>
  <brief_title>Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT</brief_title>
  <acronym>HepASA</acronym>
  <official_title>A Randomized Controlled Trial Comparing Low Molecular Weight Heparin and Aspirin to Aspirin Alone in Women With Unexplained Recurrent Pregnancy Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Sinai Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mount Sinai Hospital, Canada</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the livebirth rate of women with recurrent pregnancy loss and autoantibodies
      randomized to either low molecular weight heparin plus aspirin versus aspirin alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies of these therapeutic regimens in the population of recurrent pregnancy loss
      and autoantibodies, have not provided conclusive evidence of their efficacy due to small
      sample size and/or weak study design. We undertook a RCT of low molecular weight heparin plus
      aspirin versus aspirin alone to investigate if the low molecular weight heparin treatment
      resulted in an increased rate of livebirths as compared to treatment with aspirin alone.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    interim analysis found no difference in LB rate and lower than expected event rate
  </why_stopped>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate whether treatment with LMW heparin plus ASA results in an increased rate of livebirths compared to treatment with ASA alone.</measure>
    <time_frame>Duration of pregnancy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes included adverse events and incidence of bone loss in the two groups.</measure>
    <time_frame>pre-pregnancy through postpartum period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Recurrent Pregnancy Loss</condition>
  <condition>Antiphospholipid Antibody Syndrome</condition>
  <arm_group>
    <arm_group_label>a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose aspirin only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low molecular weight heparin and low dose aspirin</intervention_name>
    <description>Fragmin 5000 IU/day by subcutaneous injection started at time of randomization and continued until 35 weeks gestation or delivery and low dose aspirin 81 mg/day started pre-conception and continued until 35 weeks gestation or delivery</description>
    <arm_group_label>a</arm_group_label>
    <other_name>Fragmin (Dalteparin Sodium)</other_name>
    <other_name>ASA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose aspirin</intervention_name>
    <description>81 mg enteric coated started pre-pregnancy and discontinued at 35 weeks or delivery</description>
    <arm_group_label>b</arm_group_label>
    <other_name>ASA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  history of two or more unexplained consecutive pregnancy losses prior to 32 weeks

          -  presence of one of the panel of autoantibodies/thrombophilia markers

          -  confirmed pregnancy

        Exclusion Criteria:

          -  SLE

          -  known peptic ulcer disease

          -  sensitivity to ASA or heparin

          -  previous thrombotic event

          -  geographic distance from clinic

          -  failure to consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl A Laskin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor, Department of Medicine, University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hosptial</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2007</study_first_submitted>
  <study_first_submitted_qc>November 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2007</study_first_posted>
  <last_update_submitted>November 26, 2007</last_update_submitted>
  <last_update_submitted_qc>November 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2007</last_update_posted>
  <keyword>recurrent pregnancy loss</keyword>
  <keyword>lupus anticoagulant</keyword>
  <keyword>anti cardiolipin antibodies</keyword>
  <keyword>thrombophilia</keyword>
  <keyword>low molecular weight heparin</keyword>
  <keyword>aspirin</keyword>
  <keyword>randomized clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Fetal Death</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

